Torrente-Segarra, VicencUrruticoechea Arana, AnaSanchez-Andrade Fernandez, AmaliaTovar Beltran, Juan VictorMunoz Jimenez, AlejandroMartinez-Cristobal, AnnaGonzalez Ferrandez, Jose AntonioFernandez Prada, ManuelVazquez Fuentes, NoeliaCorominas, HectorGarcia-Diaz, SilviaAcosta Pereira, AsuncionRuiz Martin, Jose MiguelLamua Riazuelo, Jose RamonExposito Moliner, RosaRuiz Vilchez, DesireeVeiga Cabello, RaulCarlos Fernandez, JesusNoguera Pons, Jose RaulGarrido Punal, Noemi PatriciaGiralt Celimendiz, PedroCortes Verdu, RaulAragon Diez, AngelTomas Roura, CarlosMoll Turudi, ConcepcionTaverner Torrent, DeliaRivas Santirso, Felipe JoaquinLerma Garrido, Juan JoseGarcia Portales, RosaOrdonez Palau, SergiParedes Gonzalez-Albo, SilviaGracia Perez, AntonioConesa Mateos, ArantxaCalvo Alen, JaimeGrana Gil, JenaroNavarro Alonso, Maria PilarMartinez Blasco, Maria JesusRENACER StudyGrp2023-02-122023-02-122016-01-011439-7595http://hdl.handle.net/10668/19206Objective: To assess effectiveness and safety of certolizumab PEGol (CZP) in rheumatoid arthritis (RA) patients after 12 months of treatment and to detect predictors of response.Methods: Observational longitudinal prospective study of RA patients from 35 sites in Spain. Variables (baseline, 3- and 12-month assessment): sociodemographics, previous Disease Modifying Anti-Rheumatic Drug (DMARD) and previous Biological Therapies (BT) use; TJC, SJC, ESR, CRP, DAS28, SDAI. Response variables: TJC, SJC, CRP, ESR, and steroids dose reductions, EULAR Moderate/Good Response, SDAI response and remission, DAS28 remission. Safety variables: discontinuation due to side-effects. Descriptive, comparative and Logistic regression analyses were performed.Results: We included 168 patients: 79.2% women, mean age 54.5 years (+/- 13.2 SD), mean disease duration 7.5 years (+/- 7.3 SD). Mean number of prior DMARD: 1.4 (+/- 1.2 SD), mean number of prior BT was 0.8 (+/- 1.1). Mean time on CZP was 9.8 months (+/- 3.4 SD). A total of 71.4% were receiving CZP at 12-month assessment. Baseline predictors of response: lower prior number DMARD; low number prior BT; higher CRP, ESR, TJC, SJC, DAS28 and SDAI (penAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Certolizumab PEGolClinical practiceEfficacyRheumatoid arthritisSafetySpanish populationSurvival rateCollege-of-rheumatologyDanish danbio registryAnti-tnf therapyClinical-practiceLong-termPlus methotrexateJapanese patientsGisea registryAlpha agentsAdalimumabresearch articleopen access10.3109/14397595.2015.11012001439-7609https://figshare.com/articles/journal_contribution/_i_RENACER_i_Study_Assessment_of_12_month_efficacy_and_safety_of_168_certolizumab_PEGol_rheumatoid_arthritis_treated_patients_from_a_Spanish_multicenter_National_database_/1569185/1/files/2351590.pdf377770800004